N-Power Medicine

Executive Summary

N-Power Medicine is a clinical research technology company that integrates an always-on clinical research system into US community oncology networks. By embedding research workflows into routine clinical practice, the company creates a consented, prospective data registry that captures real-world evidence to accelerate oncology drug development. Its platform offers two primary services: Prospective External Controls, which generate synthetic control arms for clinical trials, and a Community Trial Accelerator, which enhances patient enrollment and trial operations. Founded in 2020 and headquartered in San Francisco, N-Power Medicine operates in the high-growth intersection of oncology, AI/machine learning, and drug delivery. While still in early stages with no disclosed funding or revenue, the company addresses a critical bottleneck in oncology clinical trials—poor enrollment and limited real-world data—by leveraging existing community oncology infrastructure. Its technology has the potential to significantly reduce trial costs and timelines, improve data diversity, and enable more efficient drug development. However, execution risks include market adoption, regulatory acceptance of its external control methodology, and competition from similar platforms. Conviction is moderate given the company's nascent stage and lack of public validation, but the concept addresses a clear unmet need in clinical research.

Upcoming Catalysts (preview)

• H2 2026Major Partnership with a Leading Community Oncology Network70% success
• Q3 2026Publication of Validation Study for Prospective External Controls60% success
• 2027FDA Qualification or Guidance for Platform in Regulatory Submissions30% success